Structured Review

Pfizer Inc treatment canertinib
Dose dependent inhibition of sphere formation by anticancer drugs. To compare two sphere scoring parameters of the SSS vs. “number of spheres”, H1299 (2000 cells per well) were plated in 24-well ULA plates in TS medium supplemented with indicated drugs or vehicle for 4 days. %SSS i and %n i were then calculated. Concentration of drugs were as the following: (A) <t>CI-1033:</t> + 2 μM; (B) Erlotinib: + 3 μM, ++ 6 μM, +++ 10 μM; (C) MK2206: + 0.25 μM, ++ 0.5 μM, +++ 1 μM; (D) Perifosine: + 1 μM, ++ 3 μM, +++ 5 μM; and (E) BEZ235: + 25 nM, ++ 125 nM, +++ 250 nM. The results were presented as Mean ± SEM.
Treatment Canertinib, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 89/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/treatment canertinib/product/Pfizer Inc
Average 89 stars, based on 9 article reviews
Price from $9.99 to $1999.99
treatment canertinib - by Bioz Stars, 2020-09
89/100 stars

Related Products / Commonly Used Together

erlotinib

Images

1) Product Images from "A Reliable Parameter to Standardize the Scoring of Stem Cell Spheres"

Article Title: A Reliable Parameter to Standardize the Scoring of Stem Cell Spheres

Journal: PLoS ONE

doi: 10.1371/journal.pone.0127348

Dose dependent inhibition of sphere formation by anticancer drugs. To compare two sphere scoring parameters of the SSS vs. “number of spheres”, H1299 (2000 cells per well) were plated in 24-well ULA plates in TS medium supplemented with indicated drugs or vehicle for 4 days. %SSS i and %n i were then calculated. Concentration of drugs were as the following: (A) CI-1033: + 2 μM; (B) Erlotinib: + 3 μM, ++ 6 μM, +++ 10 μM; (C) MK2206: + 0.25 μM, ++ 0.5 μM, +++ 1 μM; (D) Perifosine: + 1 μM, ++ 3 μM, +++ 5 μM; and (E) BEZ235: + 25 nM, ++ 125 nM, +++ 250 nM. The results were presented as Mean ± SEM.
Figure Legend Snippet: Dose dependent inhibition of sphere formation by anticancer drugs. To compare two sphere scoring parameters of the SSS vs. “number of spheres”, H1299 (2000 cells per well) were plated in 24-well ULA plates in TS medium supplemented with indicated drugs or vehicle for 4 days. %SSS i and %n i were then calculated. Concentration of drugs were as the following: (A) CI-1033: + 2 μM; (B) Erlotinib: + 3 μM, ++ 6 μM, +++ 10 μM; (C) MK2206: + 0.25 μM, ++ 0.5 μM, +++ 1 μM; (D) Perifosine: + 1 μM, ++ 3 μM, +++ 5 μM; and (E) BEZ235: + 25 nM, ++ 125 nM, +++ 250 nM. The results were presented as Mean ± SEM.

Techniques Used: Inhibition, Concentration Assay

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Pfizer Inc ci 1033
    Cell cycle analysis and apoptosis of SK-N-SH cells treated with <t>CI-1033</t> or erlotinib. (A) SK-N-SH cells were treated with a range of concentrations of CI-1033 or erlotinib for 24 hours and DNA content was measured by flow cytometry. The percent of cells
    Ci 1033, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ci 1033/product/Pfizer Inc
    Average 90 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    ci 1033 - by Bioz Stars, 2020-09
    90/100 stars
      Buy from Supplier

    89
    Pfizer Inc treatment canertinib
    Dose dependent inhibition of sphere formation by anticancer drugs. To compare two sphere scoring parameters of the SSS vs. “number of spheres”, H1299 (2000 cells per well) were plated in 24-well ULA plates in TS medium supplemented with indicated drugs or vehicle for 4 days. %SSS i and %n i were then calculated. Concentration of drugs were as the following: (A) <t>CI-1033:</t> + 2 μM; (B) Erlotinib: + 3 μM, ++ 6 μM, +++ 10 μM; (C) MK2206: + 0.25 μM, ++ 0.5 μM, +++ 1 μM; (D) Perifosine: + 1 μM, ++ 3 μM, +++ 5 μM; and (E) BEZ235: + 25 nM, ++ 125 nM, +++ 250 nM. The results were presented as Mean ± SEM.
    Treatment Canertinib, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 89/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/treatment canertinib/product/Pfizer Inc
    Average 89 stars, based on 9 article reviews
    Price from $9.99 to $1999.99
    treatment canertinib - by Bioz Stars, 2020-09
    89/100 stars
      Buy from Supplier

    Image Search Results


    Cell cycle analysis and apoptosis of SK-N-SH cells treated with CI-1033 or erlotinib. (A) SK-N-SH cells were treated with a range of concentrations of CI-1033 or erlotinib for 24 hours and DNA content was measured by flow cytometry. The percent of cells

    Journal: Cancer

    Article Title: Signaling of ERBB Receptor Tyrosine Kinases Promotes Neuroblastoma Growth in vitro and in vivo

    doi: 10.1002/cncr.25073

    Figure Lengend Snippet: Cell cycle analysis and apoptosis of SK-N-SH cells treated with CI-1033 or erlotinib. (A) SK-N-SH cells were treated with a range of concentrations of CI-1033 or erlotinib for 24 hours and DNA content was measured by flow cytometry. The percent of cells

    Article Snippet: Treatment with CI-1033 for 18 days resulted in a significant reduction in tumor growth (p < 0.0001).

    Techniques: Cell Cycle Assay, Flow Cytometry, Cytometry

    In vivo effects of CI-1033 and erlotinib. (A) Subcutaneous SK-N-SH xenografts were either untreated, treated with 10 mg/kg/day of erlotinib, or treated with 30 mg/kg/day of CI-1033. Tumor volume was measured every other day and all mice were sacrificed

    Journal: Cancer

    Article Title: Signaling of ERBB Receptor Tyrosine Kinases Promotes Neuroblastoma Growth in vitro and in vivo

    doi: 10.1002/cncr.25073

    Figure Lengend Snippet: In vivo effects of CI-1033 and erlotinib. (A) Subcutaneous SK-N-SH xenografts were either untreated, treated with 10 mg/kg/day of erlotinib, or treated with 30 mg/kg/day of CI-1033. Tumor volume was measured every other day and all mice were sacrificed

    Article Snippet: Treatment with CI-1033 for 18 days resulted in a significant reduction in tumor growth (p < 0.0001).

    Techniques: In Vivo, Mouse Assay

    Inhibition of targets and downstream proteins with CI-1033 and erlotinib treatment in SK-N-SH cells. SK-N-SH cells were treated with multiple concentrations of CI-1033 (A) or erlotinib (B) for 24 hours, followed by the addition of EGF (100 ng/ml) for

    Journal: Cancer

    Article Title: Signaling of ERBB Receptor Tyrosine Kinases Promotes Neuroblastoma Growth in vitro and in vivo

    doi: 10.1002/cncr.25073

    Figure Lengend Snippet: Inhibition of targets and downstream proteins with CI-1033 and erlotinib treatment in SK-N-SH cells. SK-N-SH cells were treated with multiple concentrations of CI-1033 (A) or erlotinib (B) for 24 hours, followed by the addition of EGF (100 ng/ml) for

    Article Snippet: Treatment with CI-1033 for 18 days resulted in a significant reduction in tumor growth (p < 0.0001).

    Techniques: Inhibition

    Dose dependent inhibition of sphere formation by anticancer drugs. To compare two sphere scoring parameters of the SSS vs. “number of spheres”, H1299 (2000 cells per well) were plated in 24-well ULA plates in TS medium supplemented with indicated drugs or vehicle for 4 days. %SSS i and %n i were then calculated. Concentration of drugs were as the following: (A) CI-1033: + 2 μM; (B) Erlotinib: + 3 μM, ++ 6 μM, +++ 10 μM; (C) MK2206: + 0.25 μM, ++ 0.5 μM, +++ 1 μM; (D) Perifosine: + 1 μM, ++ 3 μM, +++ 5 μM; and (E) BEZ235: + 25 nM, ++ 125 nM, +++ 250 nM. The results were presented as Mean ± SEM.

    Journal: PLoS ONE

    Article Title: A Reliable Parameter to Standardize the Scoring of Stem Cell Spheres

    doi: 10.1371/journal.pone.0127348

    Figure Lengend Snippet: Dose dependent inhibition of sphere formation by anticancer drugs. To compare two sphere scoring parameters of the SSS vs. “number of spheres”, H1299 (2000 cells per well) were plated in 24-well ULA plates in TS medium supplemented with indicated drugs or vehicle for 4 days. %SSS i and %n i were then calculated. Concentration of drugs were as the following: (A) CI-1033: + 2 μM; (B) Erlotinib: + 3 μM, ++ 6 μM, +++ 10 μM; (C) MK2206: + 0.25 μM, ++ 0.5 μM, +++ 1 μM; (D) Perifosine: + 1 μM, ++ 3 μM, +++ 5 μM; and (E) BEZ235: + 25 nM, ++ 125 nM, +++ 250 nM. The results were presented as Mean ± SEM.

    Article Snippet: Drugs and treatment Canertinib (CI-1033, Pfizer Pharmaceuticals) and Erlotinib (Selleck Chemicals) were kindly provided by Dr. Mukesh Nyati at University of Michigan.

    Techniques: Inhibition, Concentration Assay